EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.

Read more:
Gritstone Announces Presentations during Three Upcoming Investor Conferences

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

Read more from the original source:
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations

Read the rest here:
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s...

Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022

Visit link:
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone

See the original post:
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (“Lotus” or the “Company”), a trusted cannabis producer in Canada is pleased to report its Fiscal 2021 full year results and a second consecutive year reporting a profit for the year ended August 31, 2021.

View original post here:
Lotus Ventures Inc. Reports Fiscal 2021 Results

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

Continued here:
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2...

WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted below 50%. Biofrontera AG’s shareholding in Biofrontera Inc. of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG. Biofrontera Inc.’s common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BFRI” and “BFRIW,” respectively.

Read more:
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

THE WOODLANDS, Texas, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

Go here to see the original:
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, to receive gross proceeds of approximately $6.0 million.

Continued here:
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

Company announcement – No. 78 / 2021

See the original post here:
Total number of shares and voting rights in Zealand Pharma at December 30, 2021

HALIFAX, Nova Scotia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2021.

See the original post here:
MedMira Reports First Quarter Results FY2022

Key Points:

Read more here:
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease

–  Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein –

Visit link:
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations

Read the original here:
Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, the KOLs will lend their expertise and support to guide the education and clinical advancement efforts of the Human Acellular VesselTM (HAV) and help identify opportunities to advance the Company's early stage complex tissue constructs pipeline and platform.

More here:
Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

VANCOUVER, British Columbia, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. is currently tracking the number of falls involving seniors and that have been reported in the public domain during this COVID-19 pandemic. In particular, government sites such as the Canadian Institute for Health Information, online media reports and survey portals from various countries are being searched to determine these numbers as well as the nature and location of the falls in designated senior housing such as long term care, assisted living and independent living. Lui Franciosi states, “During this pandemic, seniors have likely not had the same level of exercise and therefore their body core strength is not as optimal to prevent injury. It is known that falls are the leading cause of injuries among seniors, accounting for 61 per cent of injury-related deaths and 81 per cent of injury-related hospitalizations in Canada. There are close to 5,000 deaths each year linked to seniors’ falls and nearly 100,000 hospitalizations.” The aim of this work is to better understand how many of these falls are actually predictable and whether an algorithm could be developed to help healthcare staff and families prevent falls, especially in frequent fallers.

See the article here:
Lui Franciosi Tracking Published Fall Numbers of Seniors During this COVID-19 Pandemic

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

Read more:
ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 a.m. ET.

Link:
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference

TORONTO, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”).

Read the rest here:
Cronos Group Provides Bi-Weekly MCTO Status Update